Special Issue "Epigenetic Influence on Cancer Metastasis and/or Treatment Resistance"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (15 December 2018) | Viewed by 31044
Interests: DNA methylation; cancer invasion and metastasis in breast and pancreatic cancers; carcinoma-associated fibroblasts; epithelial–mesenchymal transition; AKT signaling pathway; tumor microenvironment and immune evasion
Special Issues, Collections and Topics in MDPI journals
Special Issue in Cancers: Tumor Microenvironment and Molecular Aberrations Convey Immune Evasion
Special Issue in Cancers: The Tumor Microenvironment and Molecular Aberrations Convey Immune Evasion (Volume II)
Causes of cancer-related mortality are largely known to be involved with reduced apoptosis, resistant to radiation treatments, refractory to target or cytotoxic chemotherapies, gain of cancer stem cells and migratory potential, as well as augmented metastasis to other vital organs. Although the molecular mechanisms underlying the above mentioned aberrations were partly ascribed to acquired genetic alterations, epigenetic abnormalities were also responsible for cancer progression leading to death.
Epigenetics refers to heritable states of gene expression without alterations to the DNA sequence itself. Epigenetic changes encompass altered DNA methylation, dysregulated histone modification, abnormal chromatin remodeling, as well as aberrant expression of micro-RNAs (miRNAs) and long noncoding RNAs (lncRNAs).
This Special Issue focuses on understanding how various epigenetic programs promote cell proliferation, endow cancer cells undergo epithelial-mesenchymal transition with a gain of cancer stem cells and enhance migratory potential leading to augmented tumor metastasis, as well as increase anabolic glucose metabolism. Meanwhile, the diminished cell apoptosis processes result in treatment failure. Because epigenetic alterations are potential reversibility and relatively stable within tumor specimens, clinical applications evolved from epigenetic studies include not only implementing therapies to correct the aberrant epigenomes, but also developing epigenetics-based biomarkers.
Dr. Huey-Jen Lin
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.